The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three months to buy time to review recently submitted information. Having ...
Nov 25 (Reuters) - The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's (A71.F), opens new tab therapy for children with a rare genetic disorder that causes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results